Cargando…

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

OBJECTIVE: Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II anti-CD20 monoclonal antibody that induces potent B-cell depletion, with placebo for the treatment of LN i...

Descripción completa

Detalles Bibliográficos
Autores principales: Furie, Richard A, Aroca, Gustavo, Cascino, Matthew D, Garg, Jay P, Rovin, Brad H, Alvarez, Analia, Fragoso-Loyo, Hilda, Zuta-Santillan, Elizabeth, Schindler, Thomas, Brunetta, Paul, Looney, Cary M, Hassan, Imran, Malvar, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762029/
https://www.ncbi.nlm.nih.gov/pubmed/34615636
http://dx.doi.org/10.1136/annrheumdis-2021-220920